Copyright Reports & Markets. All rights reserved.

Global Sarcopenia Treatments Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Sarcopenia Treatments Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Presarcopenia
      • 1.4.3 Sarcopenia
      • 1.4.4 Severe Sarcopenia
    • 1.5 Market by Application
      • 1.5.1 Global Sarcopenia Treatments Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Ambulatory Surgical Centers
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Sarcopenia Treatments Market Size
    • 2.2 Sarcopenia Treatments Growth Trends by Regions
      • 2.2.1 Sarcopenia Treatments Market Size by Regions (2014-2025)
      • 2.2.2 Sarcopenia Treatments Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Sarcopenia Treatments Market Size by Manufacturers
      • 3.1.1 Global Sarcopenia Treatments Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Sarcopenia Treatments Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Sarcopenia Treatments Market Concentration Ratio (CR5 and HHI)
    • 3.2 Sarcopenia Treatments Key Players Head office and Area Served
    • 3.3 Key Players Sarcopenia Treatments Product/Solution/Service
    • 3.4 Date of Enter into Sarcopenia Treatments Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Sarcopenia Treatments Market Size by Type (2014-2019)
    • 4.2 Global Sarcopenia Treatments Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Sarcopenia Treatments Market Size (2014-2019)
    • 5.2 Sarcopenia Treatments Key Players in United States
    • 5.3 United States Sarcopenia Treatments Market Size by Type
    • 5.4 United States Sarcopenia Treatments Market Size by Application

    6 Europe

    • 6.1 Europe Sarcopenia Treatments Market Size (2014-2019)
    • 6.2 Sarcopenia Treatments Key Players in Europe
    • 6.3 Europe Sarcopenia Treatments Market Size by Type
    • 6.4 Europe Sarcopenia Treatments Market Size by Application

    7 China

    • 7.1 China Sarcopenia Treatments Market Size (2014-2019)
    • 7.2 Sarcopenia Treatments Key Players in China
    • 7.3 China Sarcopenia Treatments Market Size by Type
    • 7.4 China Sarcopenia Treatments Market Size by Application

    8 Japan

    • 8.1 Japan Sarcopenia Treatments Market Size (2014-2019)
    • 8.2 Sarcopenia Treatments Key Players in Japan
    • 8.3 Japan Sarcopenia Treatments Market Size by Type
    • 8.4 Japan Sarcopenia Treatments Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Sarcopenia Treatments Market Size (2014-2019)
    • 9.2 Sarcopenia Treatments Key Players in Southeast Asia
    • 9.3 Southeast Asia Sarcopenia Treatments Market Size by Type
    • 9.4 Southeast Asia Sarcopenia Treatments Market Size by Application

    10 India

    • 10.1 India Sarcopenia Treatments Market Size (2014-2019)
    • 10.2 Sarcopenia Treatments Key Players in India
    • 10.3 India Sarcopenia Treatments Market Size by Type
    • 10.4 India Sarcopenia Treatments Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Sarcopenia Treatments Market Size (2014-2019)
    • 11.2 Sarcopenia Treatments Key Players in Central & South America
    • 11.3 Central & South America Sarcopenia Treatments Market Size by Type
    • 11.4 Central & South America Sarcopenia Treatments Market Size by Application

    12 International Players Profiles

    • 12.1 GlaxoSmithKline
      • 12.1.1 GlaxoSmithKline Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Sarcopenia Treatments Introduction
      • 12.1.4 GlaxoSmithKline Revenue in Sarcopenia Treatments Business (2014-2019)
      • 12.1.5 GlaxoSmithKline Recent Development
    • 12.2 GTX
      • 12.2.1 GTX Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Sarcopenia Treatments Introduction
      • 12.2.4 GTX Revenue in Sarcopenia Treatments Business (2014-2019)
      • 12.2.5 GTX Recent Development
    • 12.3 Five Prime Therapeutics
      • 12.3.1 Five Prime Therapeutics Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Sarcopenia Treatments Introduction
      • 12.3.4 Five Prime Therapeutics Revenue in Sarcopenia Treatments Business (2014-2019)
      • 12.3.5 Five Prime Therapeutics Recent Development
    • 12.4 Radius Health
      • 12.4.1 Radius Health Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Sarcopenia Treatments Introduction
      • 12.4.4 Radius Health Revenue in Sarcopenia Treatments Business (2014-2019)
      • 12.4.5 Radius Health Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Sarcopenia is the degenerative loss of skeletal muscle mass (0.5-1% loss per year after the age of 50), quality and strength associated with aging.
      Sarcopenia is characterized first by a muscle atrophy, along with a reduction in muscle tissue quality, characterized by such factors as replacement of muscle fibres with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction and leading to progressive loss of muscle function and frailty.
      In 2018, the global Sarcopenia Treatments market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Sarcopenia Treatments status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Sarcopenia Treatments development in United States, Europe and China.

      The key players covered in this study
      GlaxoSmithKline
      GTX
      Five Prime Therapeutics
      Radius Health
      ...

      Market segment by Type, the product can be split into
      Presarcopenia
      Sarcopenia
      Severe Sarcopenia

      Market segment by Application, split into
      Hospitals
      Clinics
      Ambulatory Surgical Centers

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Sarcopenia Treatments status, future forecast, growth opportunity, key market and key players.
      To present the Sarcopenia Treatments development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Sarcopenia Treatments are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now